A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to test the pharmacokinetics after twice daily administration of MK-0941 or placebo in subjects with type 2 diabetes who have inadequate control on metformin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Subject has a BMI < 42 kg/m2

• Subject is taking >1500 mg metformin per day for at least 8 weeks

• Subject has HbA1c value of 7.0% and < 11% at screening

• Subject is willing to follow AHA weight maintaining diet and exercise program

• Subject is a nonsmoker for at least 6 months

Exclusion Criteria:

• Subject has type 1 diabetes

• Subject has a history of stroke or chronic seizure

• Subject has a history of neoplastic disease

• Subject has a history of gastrointestinal, cardiovascular, blood, liver kidney, respiratory, immunological or genitourinary disorders or diseases

• Subject is currently taking 2 or more diabetes medications

• Subject has glaucoma or is blind

• If female, subject is pregnant or breastfeeding

• Subject consumes > 3 alcoholic beverages per day

• Subject has had major surgery or has donated blood in the last 4 weeks